Attempts to shorten radiation protocols for intracranial tumors in dogs by reducing fraction number drastically, while maintaining an adequate total dose, have been made but hypofractionated treatments have not reached the same outcomes with median survival times of only 1-1.5 years, 4 compared to >2 years with more finely fractionated protocols. [1] [2] [3] Moreover, dogs treated with more coarsely fractionated protocols (and often lower total doses) have increase in toxicoses and impaired quality of life, especially when treated with older techniques. [5] [6] [7] [8] Ideally, such a change in protocol maintains a similar efficacy with no observable or only a slight increase in risk for toxicosis. Late radiation toxicosis in the brain remains difficult to detect with no consensus in medical literature as to which criteria should be used. Diagnostic imaging after recurrence of signs of neurologic disease provides some information as to whether worsening is because of tumor progression or late radiation toxicosis. [9] [10] [11] Conventional diagnostic imaging modalities fail to reliably differentiate active neoplastic tissue from radiation necrosis. 9, 12 In radiation therapy, the risk of toxicosis can be anticipated. In a prior study, we calculated the normal tissue complication probability (NTCP) with clinical data of former dogs with brain tumor with 10 × 4.35 Gy to be safe with a low risk of radiation-induced toxicosis for most tumor sizes and locations, given an appropriate technical radiation therapy standard. This protocol provides the same biologically effective dose (BED) as the routinely used 20 × 2.5 Gy protocol, and should theoretically result in an equal tumor control. 13 However, to implement such a new, moderately hypofractionated, 10-fraction protocol into clinical practice, we used a conservative approach: instead of using 10 × 4.35 Gy, we started with a lower dose protocol of 10 × 4 Gy. This protocol was calculated for having the "same risk" (probability estimates of late toxicosis, eg, NTCP) and hence a lower BED. As a consequence, the 10 × 4 Gy protocol was expected to have a clinically detectable inferior outcome.
The aim of this clinical study was to provide data on clinical outcome described as progression-free interval (PFI) and overall survival (OS), as well as clinical performance and the occurrence of adverse events in dogs with intracranial tumors irradiated with either 10 × 4 Gy or the traditional protocol of 20 × 2.5 Gy. We hypothesized that a clinically detectable difference of outcome for PFI, OS time or both between the 2 treatment groups should occur, because of differences in the BED given. The resulting data will be used for the future decision, whether clinical escalation of dose per fraction for the irradiation in 10 fractions can be safely attempted.
| MATERIAL AND METHODS

| Study design
Retrospective observational study.
| Dog and tumor characteristics
Client-owned dogs diagnosed with symptomatic primary intracranial tumors presented for radiotherapy at the Division of Radiation Oncology, Vetsuisse Faculty, University Zurich, Switzerland, were enrolled in the study. The intracranial tumors were diagnosed based on neurologic examination including examination of cerebrospinal fluid (CSF) and magnet resonance imaging (MRI) or computed tomography (CT). 10, 11, [14] [15] [16] [17] Radiation was delivered with a 6MV linear accelerator (Clinac iX, Varian, Palo Alto, California) equipped with a 5-mm leaf-width multileaf-collimator, using photons and 3-dimensional (3D) conformal radiation therapy (3DCRT) or intensity-modulated radiation therapy (IMRT).
Treatment planning was performed using Eclipse External Beam planning software (Eclipse treatment planning software, Varian Oncology Systems, Palo Alto, California), applying AAA-algorithm (10.0.28).
Radiation was planned isocentrically, with heterogeneity correction, by a board-certified radiation oncologist (CRB or VM). Planning-CT and daily treatments were performed under general anesthesia in sternal recumbency. Reproducible positioning was accomplished with both an individually shaped vacuum cushion (BlueBag BodyFix, Elekta AB, Stockholm, Sweden) and a custom-made bite block. 18 Target volumes and organs at risk (OAR) were contoured in a facility internal standardized manner as previously published by our research team. 13 In brief, the gross tumor volume (GTV) was delineated using coregistered contrast-enhanced CT images or CT and MRI images, in tumors with no contrast uptake T2 sequences were used for delineation of GTV. Clinical target volume (CTV), accounting for subclinical microscopic disease extension of 2-8 mm (presumed local infiltration, according to tumor type) was defined. The CTV-margin was then extended 3 dimensionally by 2 mm to define the planning target volume (PTV), accounting for setup uncertainties in daily image-guided photon treatment. OAR were segmented as described previously. 13 Additionally, for the assessment of radiation toxicosis, a volume PTV brain was computed, representing the portion of the PTV inside the calvarium. Furthermore, the ratio of the target volume to the entire brain volume (BV) was computed for each target volume.
board imaging and daily orthogonal kilovolt-images. The recommendations for specifying dose and volumes were adhered to as proposed by Keyerleber et al., 19 and in the ICRU reports 50 and 62 for 3DCRT
and ICRU report 83 for IMRT plans. [20] [21] [22] The dose was prescribed at the ICRU reference point, delivered in a protocol of either 10 × 4 Gy (40 Gy total dose) or 20 × 2.5 Gy (50 Gy total dose). According to the Swiss law and routine procedure in our clinic, a medical physicist approved all treatment plans and the IMRT treatment plans were dosimetrically verified before treatment using a phantom (OctaviusPhantom, PTW Freiburg, Germany).
Treatment was delivered with definitive-intent, on a Monday to 
and late radiation toxicosis was suspected.
| Follow-up and outcome
Clinical and neurological response at 6 months after radiotherapy was Survival analysis and analysis of PFI for the groups split by "intention to treat" and "per protocol" did not show any relevant differences to the analyses above for groups split by "as treated" factor.
| DISCUSSION
In this study, we chose a conservative approach for the 1st-time application of this moderately hypofractionated 10-fraction protocol in dogs. A short protocol with 10 fractions and the same risk for late toxicosis (NTCP), based on mathematical calculations, was compared to the standard 20-fraction protocol. 13 Based on VRTOG clinical observations, no increased occurrence of toxicosis was found. The outcome, as well as the low occurrence of adverse events in dogs irradiated with this moderately hypofractionated protocol of 10 × 4 Gy for their brain tumors was not different from the standard protocol and can be summarized as favorable.
Prior protocols used for the treatment of intracranial tumors in dogs using a lower fraction number raised the suspicion that OS was compromised by fatal acute or late radiation complications in >16%. 5, 8 Overall, large fraction sizes chosen and applied with older 2D or nonimage-guided 3D techniques cannot be recommended for safe future use. 6 For some tumor constellations with small tumor volumes in nonsensitive areas, a reduction in fraction size can safely be performed, given an appropriate technical radiation therapy standard. In the dogs that had imaging performed at progression of signs of neurologic disease, these signs could be attributed to tumor progression (local or locoregional) and based on diagnostic imaging, no late radiation toxicosis was suspected. As the latency to occurrence of radiation necrosis varies greatly, the low incidence might have been attributed to the only intermediate OS of the dogs compared to toxicosis outcomes observed in human patients. However, the incidence as well as the time of occurrence of radiation necrosis increases with increasing BED. 27 The incidence of radiation necrosis in the cerebrum is 4% for a BED >85-120 Gy 2 and increases to 17% for BED >155-190 Gy 2 and 22%
for BED >190-225 Gy 2 . 27 Calculation of BED for the protocols used in our study were on the lower end with 112.5 Gy 2 in group A and 120 Gy 2 in group B, reassuring the incidence of radiation necrosis is probably ≤4%, but might occur in some cases.
Clinical improvement as well as PFI and OS was not significantly different between the treatment groups, even if the lower BED in the 10-fraction protocol implies a lower efficacy and tumor control probability. 13 The median PFI of 22 months (95%CI: 16;27) in this study as well as the percentage of dogs free of progression at 1-and 2-years (81% and 41%) are comparable with other studies, as their 1-and 2-year proportions free of progression lie within our 95%CI range.
Also, the OS with a median of 21 months in this study (95%CI: 13;29) and the proportion alive at 1-and 2-years (70% and 47%), respectively, is comparable to reported findings. Three-dimensional measurements resulted in a "greater reduction" of tumor volume than comparing the sum product of largest diameters.
This effect occurs in human glioblastoma multiforme, suggesting 3D measurements to be preferred for accurate response assessment after radiotherapy. 30, 31 Furthermore, 2 dogs with suspected glioma had to be excluded from comparison of 2D and 3D measurements, because of a lack of contrast uptake of the brain lesion. MacDonald's response criteria were published in 1990 for assessment of CT studies limiting their use in MRI, which has since progressed to be modality of choice in brain diagnostics.
We acknowledge the limitations of the results presented herein:
The first statistical limitation was the almost-randomized design of the study impedes interpretation of the results. For statistical analysis, the "as treated" regime was applied. In this regime, the dogs are assigned to the actual treatment groups. The chronological switch from 1 protocol (group A) to another (group B) does not represent an approximation to randomization. Therefore, 2 additional "intention to treat" and A further limitation of the study was the absence of histological confirmation of the origin of the tumor in the majority of the dogs.
Diagnostic imaging represents a well-established modality for tumor diagnosis. Intracranial neoplasia can quite reliably be differentiated from non-neoplastic diseases. 10, 11, [14] [15] [16] [17] Nevertheless, accuracy for distinction between different tumor types with standard magnetic resonance imaging dropped to 70% in 1 study, making it difficult to rely on statistical differences between tumor types when no histology is available. 16 In addition the presumed tumor types were not evenly distributed between the 2 groups, causing a possible bias. Some to. In parallel to local control, potential late toxicoses resulting from lesser-fractioned protocols must also remain an important focus for the future.
